A microphysiological system model of therapy for liver micrometastases

Experimental Biology and Medicine

Volumn 239, Issue 9, 2014, Pages 1170-1179

  Clark, Amanda M ^a   Wheeler, Sarah E ^a   Taylor, Donald P ^a   Pillai, Venkateswaran C ^a   Young, Carissa L ^b   Prantil Baun, Rachelle ^c   Nguyen, Transon ^c   Stolz, Donna B ^a   Borenstein, Jeffrey T ^c   Lauffenburger, Douglas A ^b   Venkataramanan, Raman ^a   Griffith, Linda G ^b   Wells, Alan ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c CHARLES STARK DRAPER LABORATORY   (United States)

Author keywords

chemotherapeutics; liver; mammary carcinoma; Micrometastasis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450; FIBRINOGEN; UREA; UVOMORULIN;

ARTICLE; BIOREACTOR; BREAST CANCER CELL LINE; CANCER THERAPY; CELL CULTURE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; LIVER CELL; LIVER METASTASIS; LIVERCHIP MICROPHYSIOLOGICAL SYSTEM; MICROMETASTASIS; MODELS AND PHANTOMS; PHYSIOLOGY; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BREAST CARCINOMA; BREAST TUMOR; CHEMOTHERAPY; CULTURE TECHNIQUE; DRUG SCREENING; EQUIPMENT; FEMALE; HUMAN; LIVER; LIVER TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; REVIEW; TIME; TUMOR CELL LINE;

CHEMOTHERAPEUTICS; LIVER; MAMMARY CARCINOMA; MICROMETASTASIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; TIME FACTORS;

EID: 84907015391     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214532596     Document Type: Article

References (76)

1. Christiansen JJ,Rajasekaran AK.Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.Cancer Res. 2006;66:8319-26
2. Taylor DP,Wells JZ,Savol A,Chennubhotla C,Wells A.Modeling boundary conditions for balanced proliferation in metastatic latency.Clin Cancer Res. 2013;19:1063-70
3. Weinberg RA.The many faces of tumor dormancy.APMIS. 2008;116:548-51
4. O'Shaughnessy J.Extending survival with chemotherapy in metastatic breast cancer.Oncologist. 2005;10:20-9
5. Hackam DG,Redelmeier DA.Translation of research evidence from animals to humans.JAMA. 2006;296:1731-2
6. Mestas J,Hughes CC.Of mice and not men: differences between mouse and human immunology.J Immunol. 2004;172:2731-8
7. Fantozzi A,Christofori G.Mouse models of breast cancer metastasis.Breast Cancer Res. 2006;8:212-212
8. Khanna C,Hunter K.Modeling metastasis in vivo.Carcinogenesis. 2005;26:513-23
9. Teicher BA.Tumor models for efficacy determination.Mol Cancer Ther. 2006;5:2435-43
10. Junttila MR,de Sauvage FJ.Influence of tumour micro-environment heterogeneity on therapeutic response.Nature. 2013;501:346-54
11. Slaney CY,Rautela J,Parker BS.The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.Cancer Res. 2013;73:5852-7
12. Domenech M,Bjerregaard R,Bushman W,Beebe DJ.Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth.Integr Biol (Camb). 2012;4:142-52
13. Gomez EW,Chen QK,Gjorevski N,Nelson CM.Tissue geometry patterns epithelial-mesenchymal transition via intercellular mechanotransduction.J Cell Biochem. 2010;110:44-51
14. Nelson CM,Vanduijn MM,Inman JL,Fletcher DA,Bissell MJ.Tissue geometry determines sites of mammary branching morphogenesis in organotypic cultures.Science. 2006;314:298-300
15. Ridky TW,Chow JM,Wong DJ,Khavari PA.Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia.Nat Med. 2010;16:1450-5
16. Shaw KR,Wrobel CN,Brugge JS.Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis.J Mammary Gland Biol Neoplasia. 2004;9:297-310
17. Stroock AD,Fischbach C.Microfluidic culture models of tumor angiogenesis.Tissue Eng Part A. 2010;16:2143-6
18. Grever MR, Grieshaber CK. Toxicology by Organ System. In: Bast RC Jr, Kufe DW, Pollock RE, et al. (eds) Holland-Frei Cancer Medicine. 5th edition. Hamilton (ON): BC Decker; 2000. Chapter 45. Available at: http://www.ncbi.nlm.nih.gov/books/NBK20792/.
19. Pickren J, Tsukada Y, Lane W. Liver metastasis: analysis of autopsy data. In: Weiss L, Gilbert L (eds) Liver metastasis. Boston, MA: G.K. Hall Medical Publishers, 1982, pp.2–18.
20. Guengerich FP,Turvy CG.Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples.J Pharmacol Exp Ther. 1991;256:1189-94
21. Crispe IN.The liver as a lymphoid organ.Annu Rev Immunol. 2009;27:147-63
22. Shimada T,Yamazaki H,Mimura M,Inui Y,Guengerich FP.Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.J Pharmacol Exp Ther. 1994;270:414-23
23. Slaughter RL,Edwards DJ.Recent advances: the cytochrome P450 enzymes.Ann Pharmacother. 1995;29:619-24
24. Wilkinson GR.Drug metabolism and variability among patients in drug response.N Engl J Med. 2005;352:2211-21
25. Fu L,Lee CC.The circadian clock: pacemaker and tumour suppressor.Nat Rev Cancer. 2003;3:350-61
26. Levi F,Schibler U.Circadian rhythms: mechanisms and therapeutic implications.Annu Rev Pharmacol Toxicol. 2007;47:593-28
27. Godoy P,Hewitt NJ,Albrecht U,Andersen ME,Ansari N,Bhattacharya S,Bode JG,Bolleyn J,Borner C,Bottger J,Braeuning A,Budinsky RA,Burkhardt B,Cameron NR,Camussi G,Cho CS,Choi YJ,Craig Rowlands J,Dahmen U,Damm G,Dirsch O,Donato MT,Dong J,Dooley S,Drasdo D,Eakins R,Ferreira KS,Fonsato V,Fraczek J,Gebhardt R,Gibson A,Glanemann M,Goldring CE,Gomez-Lechon MJ,Groothuis GM,Gustavsson L,Guyot C,Hallifax D,Hammad S,Hayward A,Haussinger D,Hellerbrand C,Hewitt P,Hoehme S,Holzhutter HG,Houston JB,Hrach J,Ito K,Jaeschke H,Keitel V,Kelm JM,Kevin Park B,Kordes C,Kullak-Ublick GA,LeCluyse EL,Lu P,Luebke-Wheeler J,Lutz A,Maltman DJ,Matz-Soja M,McMullen P,Merfort I,Messner S,Meyer C,Mwinyi J,Naisbitt DJ,Nussler AK,Olinga P,Pampaloni F,Pi J,Pluta L,Przyborski SA,Ramachandran A,Rogiers V,Rowe C,Schelcher C,Schmich K,Schwarz M,Singh B,Stelzer EH,Stieger B,Stober R,Sugiyama Y,Tetta C,Thasler WE,Vanhaecke T,Vinken M,Weiss TS,Widera A,Woods CG,Xu JJ,Yarborough KM,Hengstler JG.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Arch Toxicol. 2013;87:1315-30
28. Debnath J,Brugge JS.Modelling glandular epithelial cancers in three-dimensional cultures.Nat Rev Cancer. 2005;5:675-88
29. Dunn JC,Tompkins RG,Yarmush ML.Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration.Biotechnol Prog. 1991;7:237-45
30. Khetani SR,Bhatia SN.Microscale culture of human liver cells for drug development.Nat Biotechnol. 2008;26:120-6
31. Bissell DM,Arenson DM,Maher JJ,Roll FJ.Support of cultured hepatocytes by a laminin-rich gel. Evidence for a functionally significant subendothelial matrix in normal rat liver.J Clin Invest. 1987;79:801-12
32. Clayton DF,Harrelson AL,Darnell JE.Dependence of liver-specific transcription on tissue organization.Mol Cell Biol. 1985;5:2623-32
33. Godoy P,Hengstler JG,Ilkavets I,Meyer C,Bachmann A,Muller A,Tuschl G,Mueller SO,Dooley S.Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis.Hepatology. 2009;49:2031-43
34. Koide N,Shinji T,Tanabe T,Asano K,Kawaguchi M,Sakaguchi K,Koide Y,Mori M,Tsuji T.Continued high albumin production by multicellular spheroids of adult rat hepatocytes formed in the presence of liver-derived proteoglycans.Biochem Biophys Res Commun. 1989;161:385-91
35. Tong JZ,De Lagausie P,Furlan V,Cresteil T,Bernard O,Alvarez F.Long-term culture of adult rat hepatocyte spheroids.Exp Cell Res. 1992;200:326-32
36. Takeshita K,Bowen WC,Michalopoulos GK.Three-dimensional culture of hepatocytes in a continuously flowing medium.In Vitro Cell Dev Biol Anim. 1998;34:482-85
37. Allen JW,Khetani SR,Bhatia SN.In vitro zonation and toxicity in a hepatocyte bioreactor.Toxicol Sci. 2005;84:110-19
38. Novik E,Maguire TJ,Chao P,Cheng KC,Yarmush ML.A microfluidic hepatic coculture platform for cell-based drug metabolism studies.Biochem Pharmacol. 2010;79:1036-44
39. Chao Y,Wu Q,Acquafondata M,Dhir R,Wells A.Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases.Cancer Microenviron. 2012;5:19-28
40. Chao YL,Shepard CR,Wells A.Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition.Mol Cancer. 2010;9:179-179
41. Yates C,Shepard CR,Papworth G,Dash A,Beer Stolz D,Tannenbaum S,Griffith L,Wells A.Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression.Adv Cancer Res. 2007;97:225-46
42. Yates CC,Shepard CR,Stolz DB,Wells A.Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin.Br J Cancer. 2007;96:1246-52
43. Chao Y,Wu Q,Shepard C,Wells A.Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance.Clin Exp Metastasis. 2012;29:39-50
44. Wheeler S, Borenstein J, Clark AM, Ebrahimkhani M, Fox IJ, Griffith L, Inman W, Lauffenburger DA, Nguyen T, Pillai VC, Prantil-Baun R, Stolz DB, Taylor DP, Ulrich T, Venkataramanan R, Wells A, Young C. All-human microphysical model of metastasis therapy. Stem Cell Res Ther 2013;4(Supp 1):S11.
45. Hewes JC,Riddy D,Morris RW,Woodrooffe AJ,Davidson BR,Fuller B.A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy.J Hepatol. 2006;45:263-70
46. Hengstler JG,Brulport M,Schormann W,Bauer A,Hermes M,Nussler AK,Fandrich F,Ruhnke M,Ungefroren H,Griffin L,Bockamp E,Oesch F,von Mach MA.Generation of human hepatocytes by stem cell technology: definition of the hepatocyte.Expert Opin Drug Metab Toxicol. 2005;1:61-74
47. Knobeloch D,Ehnert S,Schyschka L,Buchler P,Schoenberg M,Kleeff J,Thasler WE,Nussler NC,Godoy P,Hengstler J,Nussler AK.Human hepatocytes: isolation, culture, and quality procedures.Methods Mol Biol. 2012;806:99-120
48. Pillai VC,Strom SC,Caritis SN,Venkataramanan R.A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS.J Pharm Biomed Anal. 2013;74:126-32
49. Wells RG.The role of matrix stiffness in regulating cell behavior.Hepatology. 2008;47:1394-1400
50. Chaffer CL,Brennan JP,Slavin JL,Blick T,Thompson EW,Williams ED.Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.Cancer Res. 2006;66:11271-8
51. Kowalski PJ,Rubin MA,Kleer CG.E-cadherin expression in primary carcinomas of the breast and its distant metastases.Breast Cancer Res. 2003;5:R217-222
52. Tarin D,Thompson EW,Newgreen DF.The fallacy of epithelial mesenchymal transition in neoplasia.Cancer Res. 2005;65:5996-6000
53. Wells A,Yates C,Shepard CR.E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.Clin Exp Metastasis. 2008;25:621-8
54. Horning JL,Sahoo SK,Vijayaraghavalu S,Dimitrijevic S,Vasir JK,Jain TK,Panda AK,Labhasetwar V.3-D tumor model for in vitro evaluation of anticancer drugs.Mol Pharm. 2008;5:849-62
55. Mitra M,Mohanty C,Harilal A,Maheswari UK,Sahoo SK,Krishnakumar S.A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs.Mol Vis. 2012;18:1361-78
56. Sung JH,Shuler ML.A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs.Lab Chip. 2009;9:1385-94
57. Lee GY,Kenny PA,Lee EH,Bissell MJ.Three-dimensional culture models of normal and malignant breast epithelial cells.Nat Methods. 2007;4:359-65
58. Levi F,Focan C,Karaboue A,de la Valette V,Focan-Henrard D,Baron B,Kreutz F,Giacchetti S.Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.Adv Drug Deliv Rev. 2007;59:1015-35
59. Lee C,Raffaghello L,Brandhorst S,Safdie FM,Bianchi G,Martin-Montalvo A,Pistoia V,Wei M,Hwang S,Merlino A,Emionite L,de Cabo R,Longo VD.Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy.Sci Transl Med. 2012;4:124-7
60. Ohdo S.Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs.J Pharmacol Sci. 2007;103:155-8
61. Bernabe DG,Tamae AC,Biasoli ER,Oliveira SH.Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinomas.Brain Behv Immun. 2011;25:574-83
62. Aguirre-Ghiso JA.Models, mechanisms and clinical evidence for cancer dormancy.Nat Rev Cancer. 2007;7:834-46
63. Barkan D,El Touny LH,Michalowski AM,Smith JA,Chu I,Davis AS,Webster JD,Hoover S,Simpson RM,Gauldie J,Green JE.Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment.Cancer Res. 2010;70:5706-16
64. Wendt MK,Taylor MA,Schiemann BJ,Schiemann WP.Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.Mol Biol Cell. 2011;22:2423-35
65. Matsusue R,Kubo H,Hisamori S,Okoshi K,Takagi H,Hida K,Nakano K,Itami A,Kawada K,Nagayama S,Sakai Y.Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.Ann Surg Oncol. 2009;16:2645-53
66. Paschos KA,Majeed AW,Bird NC.Role of Kupffer cells in the outgrowth of colorectal cancer liver metastases.Hepatol Res. 2010;40:83-94
67. Gao D,Nolan DJ,Mellick AS,Bambino K,McDonnell K,Mittal V.Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis.Science. 2008;319:195-8
68. Hochst B,Schildberg FA,Bottcher J,Metzger C,Huss S,Turler A,Overhaus M,Knoblich A,Schneider B,Pantelis D,Kurts C,Kalff JC,Knolle P,Diehl L.Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice.Hepatology. 2012;56:1924-33
69. Sceneay J,Smyth MJ,Moller A.The pre-metastatic niche: finding common ground.Cancer Metastasis Rev. 2013;32:449-64
70. Erler JT,Weaver VM.Three-dimensional context regulation of metastasis.Clin Exp Metastasis. 2009;26:35-49
71. Ideker T,Winslow LR,Lauffenburger AD.Bioengineering and systems biology.Ann Biomed Eng. 2006;34:257-64
72. Joughin BA,Naegle KM,Huang PH,Yaffe MB,Lauffenburger DA,White FM.An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells.Mol Biosyst. 2009;5:59-67
73. Dash A,Inman W,Hoffmaster K,Sevidal S,Kelly J,Obach RS,Griffith LG,Tannenbaum SR.Liver tissue engineering in the evaluation of drug safety.Expert Opin Drug Metab Toxicol. 2009;5:1159-74
74. Siolas D,Hannon GJ.Patient-derived tumor xenografts: transforming clinical samples into mouse models.Cancer Res. 2013;73:5315-19
75. Hirschhaeuser F,Sattler UG,Mueller-Klieser W.Lactate: a metabolic key player in cancer.Cancer Res. 2011;71:692125-692125
76. Miller MA,Barkal L,Jeng K,Herrlich A,Moss M,Griffith LG,Lauffenburger DA.Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.Integr Biol (Camb). 2011;3:422-38